Search Results 1321-1330 of 16382 for alt

1. Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma - Mayo Clinic

   Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN. Participating Mayo Clinic locations. Study statuses change often. Please contact ...

2. A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma - Mayo Clinic

   Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x IULN (must be documented within 28 days prior to registration for adults [age 18 ...

3. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial - Mayo Clinic

   * Alanine transaminase (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (obtained =\< 14 days prior to registration). * Registration must be completed ...

4. A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer - Mayo Clinic

   ... (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 X institutional ULN; Creatinine ≤ 1.5 X institutional ULN or creatinine clearance ≥ 60 mL/min/1.73 ...

5. A Study Of Home-Based Therapy For Glioma - Mayo Clinic

   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x ULN (≤5 x ULN for patients with baseline liver disease). Negative pregnancy test ...

6. AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma - Mayo Clinic

   ... [ALT]) ≤ 2.5 times ULN; Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels > 1.5 x ULN; A non ...

7. JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations - Mayo Clinic

   ALT/AST ≤ 2.5 times the ULN, or < 5 times the ULN for subjects with liver metastases. Negative serum pregnancy test within 14 days prior to the first dose ...

8. A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol) - Mayo Clinic

   Alanine aminotransferase (ALT) ≤ 2.5 x ULN; ≤ 5 x ULN if liver metastases are present (within 28 days prior to step 2 registration). Patients with ...

9. Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis - Mayo Clinic

   Subjects with AST and ALT < 5 × ULN. 8. Subjects with hemoglobin ≥ 10 g/dL. 9. Subjects with total bilirubin < 2× ULN. 10. Men and women of child-bearing ...

10. Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery - Mayo Clinic

    Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN OR ≤ 5 X ULN for patients with liver metastases;; Creatinine ≤ 1.5 X ULN and CrCL ...